



ASX & Media Release

PAT-DX1 draft GLP toxicology reports received

Melbourne, Australia; 24 May 2023: Patrys Limited (ASX: PAB, “Patrys” or the “Company”), a therapeutic antibody development company, is pleased to announce that it has received favourable draft reports for two recently completed Good Laboratory Practice (GLP) toxicology studies testing PAT-DX1 in rats and a non-human primate species.

In these draft reports there were no safety or tolerability issues associated with PAT-DX1 in either species that are likely to impact on the ability to initiate human clinical studies with PAT-DX1. This is consistent with the favourable safety profile we have seen for PAT-DX1 in our non-GLP toxicology studies previously. Two additional draft reports that will provide further toxicological characterisation of the GLP PAT-DX1 antibody material are expected by the end of July. Patrys expects to receive the final reports, which will be used to support the application to initiate a clinical trial of PAT-DX1, towards the end of the year.

Patrys Chief Executive Officer and Managing Director, Dr. James Campbell said: “We are very pleased to have completed these two toxicology studies in rats and a non-human primates and have them confirm the favourable safety profile that we have seen for PAT-DX1 to date. These studies are expected to complete the regulatory safety requirements that need to be fulfilled in order to start a clinical trial in cancer patients. While these are still draft reports, they typically would identify any major issues or areas of concern and so we do not expect the findings presented in the final report to differ materially. In the meantime, we believe that we will be able to restart manufacturing for the PAT-DX1 material for the clinical trial in Q3, CY2023.”

-Ends-

This announcement is authorised for release by the Board of Directors of Patrys Limited.

For further information, please contact:

General enquiries

James Campbell
Chief Executive Officer
P: +61 3 96703273
info@patrys.com

Media enquiries:

Haley Chartres
HACK
P: +61 423 139 163
haley@hck.digital

**Registered Office Address**

Level 4, 100 Albert Road
South Melbourne VIC 3205

About Patrys Limited

Based in Melbourne, Australia, Patrys (ASX:PAB) is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. More information can be found at www.patrys.com.

About Patrys' deoxymab 3E10 platform: Patrys' deoxymab platform is based on the deoxymab 3E10 antibody that was first identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). While most antibodies bind to cell surface markers, deoxymab 3E10 penetrates into the cell nuclei and binds directly to DNA where it inhibits DNA repair processes. Cancer cells often have high levels of mutations and underlying deficiencies in the DNA repair mechanisms. For these reasons, the additional inhibition of the DNA repair processes by deoxymab 3E10 can kill cancer cells, but appears to have little impact on normal cells. As a single agent, deoxymab 3E10 has been shown to significantly enhance the efficacy of both chemo- and radiotherapies. Further, deoxymab 3E10 can be conjugated to nanoparticles to target delivery of chemotherapeutics and imaging agents to tumours.

Patrys has developed two humanised forms of deoxymab 3E10, both which have improved activity over the original deoxymab 3E10 antibody. PAT-DX1 is a dimer (two joined subunits) of the short chain from the binding domain of deoxymab 3E10, while PAT-DX3 is a full-sized IgG antibody. In a range of pre-clinical studies, PAT-DX1 has shown significant ability to kill cancer cells in cell models, human tumour explants, xenograft and orthotopic models. PAT-DX1 has been shown to cross the blood brain barrier, reduce tumour size, and increase survival in multiple animal models of brain cancer, other cancers, and cancer metastases. PAT-DX1 is tumour-agnostic, meaning that it can target many different tumour types in the body, regardless of specific tumour antigens. Patrys believes that PAT-DX1 may have application across a wide range of cancers including gliomas, melanomas, prostate, breast, pancreatic and ovarian cancers.

Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumours. This allows specific delivery of cancer drugs to multiple types of cancer while having minimal impact on normal, healthy cells.

Patrys' rights to deoxymab 3E10 are part of a worldwide license to develop and commercialise a portfolio of novel anti-DNA antibodies and antibody fragments, variants and conjugates discovered at Yale University as anti-cancer and diagnostic agents. Six patents covering the unconjugated form of deoxymab 3E10 (and derivatives thereof) have already been granted (Europe, Japan, China, and 3 in the USA), and five patents covering nanoparticle conjugation have been granted (Australia, Canada, China, India and the USA).